• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2025, Vol. 42 ›› Issue (4): 311-314.

• 药品评价 • 上一篇    下一篇

基于关联规则的参芪扶正注射液临床应用规律探析

闫沛沛, 朱振兴, 刘永新, 陶继阳, 李克   

  1. 郑州市中医院药学部, 河南 郑州 450007
  • 收稿日期:2025-05-09 修回日期:2025-07-22 接受日期:2025-10-10 出版日期:2025-08-28 发布日期:2025-10-11
  • 基金资助:
      河南省中医药科学研究专项课题 (2023ZY2150);中国老年学和老年医学学会肿瘤康复郑州市中医院基地科研课题(ZZSZYY20220106)

Analysis of the Clinical Application of Shenqi Fuzheng Injection Based on Association Rules

 YAN Peipei, ZHU Zhenxing, LIU Yongxin, TAO Jiyang, LI Ke   

  1. Department of Pharmacy, Zhengzhou Hospital of Traditional Chinese Medicine, Henan Zhengzhou 450007, China
  • Received:2025-05-09 Revised:2025-07-22 Accepted:2025-10-10 Online:2025-08-28 Published:2025-10-11

摘要: 目的:通过对郑州市某中医医院2019年1月至2023年12月间参芪扶正注射液的真实世界数据进行回顾性分析,研究该药物的临床应用规律。方法:从医院HIS数据库中提取5年内参芪扶正注射液的相关信息,应用IBM SPSS Modeler18.0软件中网状分析和Apriori算法进行“药品-药品”和“药品-类别”关联规则分析。结果:参芪扶正注射液主要用于65岁及以上老年患者,涉及使用科室16个,中医证候诊断217个;临床与其他药物联合使用较多,联合单药品种主要为复方氨基酸注射液、复方苦参注射液等,联合药物类别主要为抗感染药、清热解毒药、活血化瘀药等。结论:参芪扶正注射液在临床上存在用药风险,应遵循中医辨证论治使用,建立相关使用规范,加强用药监测,保障患者用药安全。

关键词: 参芪扶正注射液, 真实世界研究, 关联规则, 合理用药

Abstract:    Objective: Through a retrospective study of the real-world data of Shenqi fuzheng injection from January 2019 to December 2023 in a traditional Chinese medicine hospital in Zhengzhou city, the clinical application characteristics were analyzed. Methods: The relevant information of Shenqi fuzheng injection in 5 years was extracted from the HIS database of the hospital. The network analysis and Apriori algorithm in IBM SPSS Modeler18.0 software were used to analyze the association rules of drug-drug and drug-category. Results: Shenqi fuzheng injection was mainly used for elderly patients aged 65 and over, involving 16 departments and 217 TCM syndrome diagnosis. Clinically, it is often used in combination with other drugs. The combined single drug species are mainly Compound Amino Acids Injection, Fufang Kushen Injection, etc. The combined drug categories are mainly anti-infective drugs, heat-clearing and detoxifying proprietary TCM, and blood-activating and stasis-removing proprietary TCM. Conclusion: Shenqi fuzheng injection has medication risks in clinical practice. It should follow the use of TCM syndrome differentiation and treatment, establish relevant use norms, strengthen medication monitoring, and ensure the safety of medication.

Key words: Shenqi fuzheng injection, Real-world study, Association rules, Rational drug use

中图分类号: